{
    "title": "Imidazo[1,2‑a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells",
    "id": "jm9b01910",
    "journal": "Journal of Medicinal Chemistry",
    "reactions": [
        {
            "text": "The commercially available 2-amino-5-bromo pyridine 1 was treated with the suitably substituted 2-bromo-1-phenylethan-1-one, in the presence of potassium carbonate, to achieve the corresponding 2-phenyl-imidazo[1,2-a]pyridines 2a–e. Coupling the obtained heterocycles with differently substituted phenylboronic acids, performed in the presence of Pd(OAc)2 and PPh3 as the catalysts, provided the desired inhibitors. Compounds 3l,m were synthesized following the alternative synthetic sequence described in Scheme 2, which allowed researchers to get the imidazo[1,2-a]pyridine derivatives with comparable yields.",
            "product": "2a–e",
            "reactants": "1, 2-bromo-1-phenylethan-1-one, 2-amino-5-bromo pyridine",
            "catalyst": "potassium carbonate"
        },
        {
            "text": "The commercially available 2-amino-5-bromo pyridine 1 was treated with the suitably substituted 2-bromo-1-phenylethan-1-one, in the presence of potassium carbonate, to achieve the corresponding 2-phenyl-imidazo[1,2-a]pyridines 2a–e. Coupling the obtained heterocycles with differently substituted phenylboronic acids, performed in the presence of Pd(OAc)2 and PPh3 as the catalysts, provided the desired inhibitors. Compounds 3l,m were synthesized following the alternative synthetic sequence described in Scheme 2, which allowed researchers to get the imidazo[1,2-a]pyridine derivatives with comparable yields.",
            "product": "3l,m",
            "reactants": "1, 2-bromo-1-phenylethan-1-one, 2-amino-5-bromo pyridine"
        },
        {
            "text": "Coupling 2-amino-5-bromopyridine 1 with the appropriate phenylboronic acids, under the experimental conditions outlined above, gave the intermediate 5-(4-chlorophenyl)pyridin-2-amine 4, which was cyclized to the desired 2-phenyl-imidazo[1,2-a]pyrimidines 3l,m by reaction with 2-bromo-1-(4- substitutedphenyl)eth an-1-one. 7-Substituted-imidazo[1,2-a]pyridines, 7a–i, represented in Scheme 3, were obtained following similar reactions.",
            "product": "5-(4-chlorophenyl)pyridin-2-amine, 4",
            "reactants": "phenylboronic acids, 1, 2-amino-5-bromopyridine"
        },
        {
            "text": "Coupling 2-amino-5-bromopyridine 1 with the appropriate phenylboronic acids, under the experimental conditions outlined above, gave the intermediate 5-(4-chlorophenyl)pyridin-2-amine 4, which was cyclized to the desired 2-phenyl-imidazo[1,2-a]pyrimidines 3l,m by reaction with 2-bromo-1-(4- substitutedphenyl)eth an-1-one. 7-Substituted-imidazo[1,2-a]pyridines, 7a–i, represented in Scheme 3, were obtained following similar reactions.",
            "product": "3l,m, 2-phenyl-imidazo[1,2-a]pyrimidines",
            "reactants": "2-bromo-1-(4- substitutedphenyl)eth an-1-one, 4",
            "reaction type": "cyclized"
        },
        {
            "text": "The commercially available 2-amino-4-bromo pyridine 5 and the appropriate 2-bromo-1-phenylethan-1-ones gave the key intermediates 7-bromo-2-phenylimidazo[1,2-a]pyridines 6a–c, which were converted into the target inhibitors 7a–i by reaction with different phenyl boronic acids, under the customary coupling conditions in the presence of Pd(OAc)2 and PPh3 as the catalysts.",
            "product": "7-bromo-2-phenylimidazo[1,2-a]pyridines",
            "reactants": "2-amino-4-bromo pyridine, 5, 2-bromo-1-phenylethan-1-ones",
            "catalyst": "Pd(OAc)2, PPh3"
        },
        {
            "text": "The commercially available 2-amino-4-bromo pyridine 5 and the appropriate 2-bromo-1-phenylethan-1-ones gave the key intermediates 7-bromo-2-phenylimidazo[1,2-a]pyridines 6a–c, which were converted into the target inhibitors 7a–i by reaction with different phenyl boronic acids, under the customary coupling conditions in the presence of Pd(OAc)2 and PPh3 as the catalysts.",
            "product": "6a–c",
            "reactants": "2-amino-4-bromo pyridine, 5, 2-bromo-1-phenylethan-1-ones"
        },
        {
            "text": "The commercially available 2-amino-4-bromo pyridine 5 and the appropriate 2-bromo-1-phenylethan-1-ones gave the key intermediates 7-bromo-2-phenylimidazo[1,2-a]pyridines 6a–c, which were converted into the target inhibitors 7a–i by reaction with different phenyl boronic acids, under the customary coupling conditions in the presence of Pd(OAc)2 and PPh3 as the catalysts.",
            "product": "7a–i",
            "reactants": "6a–c, phenyl boronic acids",
            "reaction type": "coupling",
            "catalyst": "Pd(OAc)2, PPh3"
        },
        {
            "text": "A solution of 5-bromopyridin-2-amine 1 (1.00 mmol) in ethanol was added with the suitably substituted 2-bromo-1-phenylethan-1-one (1.00 mmol) and potassium carbonate (138 mg, 1.00 mmol), and the resulting mixture was refluxed under stirring until the disappearance of the starting material (TLC analysis). After cooling, the crude obtained was evaporated to dryness; then water was added to the residue, and the desired heterocycle, 2d,e, separated as a white solid, was collected by filtration, purified through recrystallization from the suitable solvent and characterized with physio-chemical and spectroscopic data.",
            "product": "2d,e",
            "reactants": "potassium carbonate, 1, 2-bromo-1-phenylethan-1-one, 5-bromopyridin-2-amine",
            "solvent": "ethanol"
        },
        {
            "text": "A solution of 5-(4-chlorophenyl)pyridin-2-amine4 (1.00 mmol) in ethanol was added with the suitably substituted 2-bromo-1-phenylethan-1-one (1.00 mmol) and potassium carbonate (138 mg, 1.00 mmol), and the resulting mixture was refluxed under stirring until the disappearance of the starting material (TLC analysis). After cooling, the crude obtained was evaporated to dryness; then water was added to the residue, and the desired heterocycle 3l,m, separated as a white solid, was collected by filtration, purified through recrystallization from the suitable solvent, and characterized with physio-chemical and spectroscopic data.",
            "product": "3l,m",
            "reactants": "potassium carbonate, 5-(4-chlorophenyl)pyridin-2-amine4, 2-bromo-1-phenylethan-1-one",
            "solvent": "ethanol"
        },
        {
            "text": "A solution of 4-bromopyridin-2-amine 5 (1.00 mmol) in ethanol was added with the suitably substituted 2-bromo-1-phenylethan-1-one (1.00 mmol) and potassium carbonate (138 mg, 1.00 mmol), and the resulting mixture was refluxed under stirring until the disappearance of the starting material (TLC analysis). After cooling, the crude obtained was evaporated to dryness; then water was added to the residue, and the desired heterocycle, 6a–c, separated as a white solid, was collected by filtration, purified through recrystallization from the suitable solvent, and characterized with physio-chemical and spectroscopic data.",
            "product": "6a–c",
            "reactants": "5, 4-bromopyridin-2-amine, 2-bromo-1-phenylethan-1-one, potassium carbonate",
            "solvent": "ethanol"
        },
        {
            "text": "Crystals of ALDH1A3 in complex with 3a (PDB deposition name GA11) and 3q (PDB deposition name LQ45) were obtained by using the vapor-diffusion technique in sitting drop and applying a spare-matrix-based strategy with a crystallization robot (Oryx4, Douglas Instruments). The best crystals of 3a-ALDH1A3 were grown by mixing 0.5 μL of protein solution at a concentration of 8 mg/mL, preincubated with 1 mM NAD+ and 300 μM 3a, with an equal volume of a reservoir solution containing 2.4 M sodium malonate, pH 7.0, and equilibrated against 50 μL of the reservoir solution, at 20 °C in about 30 days. For X-ray data collection, crystals were quickly equilibrated in a solution containing the crystallization buffer and 12.5% glycerol as cryo-protectant and flash frozen at 100 K in liquid nitrogen.",
            "product": "3a-ALDH1A3",
            "reactants": "protein, NAD+, sodium malonate, 3a",
            "temperature": "20 °C",
            "time": "30 days"
        },
        {
            "text": "Crystals of ALDH1A3 in complex with 3a (PDB deposition name GA11) and 3q (PDB deposition name LQ45) were obtained by using the vapor-diffusion technique in sitting drop and applying a spare-matrix-based strategy with a crystallization robot (Oryx4, Douglas Instruments). The best crystals of 3a-ALDH1A3 were grown by mixing 0.5 μL of protein solution at a concentration of 8 mg/mL, preincubated with 1 mM NAD+ and 300 μM 3a, with an equal volume of a reservoir solution containing 2.4 M sodium malonate, pH 7.0, and equilibrated against 50 μL of the reservoir solution, at 20 °C in about 30 days. For X-ray data collection, crystals were quickly equilibrated in a solution containing the crystallization buffer and 12.5% glycerol as cryo-protectant and flash frozen at 100 K in liquid nitrogen.",
            "product": "3q",
            "reactants": "sodium malonate, 3a",
            "reaction type": "vapor-diffusion"
        }
    ]
}